

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3.

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Control Enter the part of the policy of th

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance,

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Song 1



Section 1. Identifying Infor	mation		
Given Name (First Name) Lai-Rong	Surname (Last Name Song	e)	3. Date 27-February-2020
4. Are you the corresponding author?	Yes V No	Corresponding Author's N Jun-Ting Zhang	lame
Manuscript TitlePrognostic and predictive value of all	n immune infiltration sigr	nature in diffuse lower-grad	de gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	ı know it)		
Section 2. The Work Under	Consideration for Pu	ublication	
Did you or your institution at any time re etc.) for any aspect of the submitted wor preparation, statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the submitted work.	k (including but not limited		
Section 3. Relevant financia	al activities outside t	he submitted work	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you Are there any relevant conflicts of interest' Yes No			
Section 4. Intellectual Bron	erty Patents & Cop	vrighte	
intellectual Prop	erty ratents & Cop	yrigints	
Do you have any patents, whether p	lanned, pending or issue	ed, broadly relevant to the	w Yes V No

Song 2



Cootion F			
Section 5.	Relationships not covered above		
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?		
	owing relationships/conditions/circumstances are present (explain below):		
No other rel interest	ationships/conditions/circumstances that present a potential conflict of		
	At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.		
Section 6.	Disclosure Statement		
Based on the a box below.	bove disclosures, this form will automatically generate a disclosure statement, which will appear in the		
Dr. Song has n	nothing to disclose.		

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Song 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3.

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Quantification an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance,

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Weng 1



Section 1. Identifying Information	mation		
Given Name (First Name) Jian-Cong	Surname (Last Name) Weng)	3. Date 27-February-2020
4. Are you the corresponding author?	Yes V No	Corresponding Author's N Jun-Ting Zhang	lame
Manuscript TitlePrognostic and predictive value of ar	n immune infiltration signa	ature in diffuse lower-grad	de gliomas
Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	know it)		
Section 2. The Work Under	Consideration for Pu	blication	
Did you or your institution at any time re etc.) for any aspect of the submitted worl preparation, statistical analysis, etc.)? Are there any relevant conflicts of int	k (including but not limited to		
Section 3. Relevant financia	al activities outside th	e submitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you Are there any relevant conflicts of interest' Yes No			
Section 4. Intellectual Prope	erty Patents & Copy	/rights	
Do you have any patents, whether pl	anned, pending or issued	d, broadly relevant to the	w

Weng 2



On officer F	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance or encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
	Disclosure Statement
Based on the all box below.	bove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Weng has r	nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Weng 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3.

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Quantification an entity, generally [but not always] paid to vour organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance,

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Li 1



Section 1. Identifying Inform	mation		
Given Name (First Name) Cheng-Bei	Surname (Last Name) Li)	3. Date 27-February-2020
4. Are you the corresponding author?	Yes V No	Corresponding Author's N Jun-Ting Zhang	lame
5. Manuscript Title Prognostic and predictive value of ar	n immune infiltration signa	ature in diffuse lower-grad	de gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	know it)	_	
Section 2			
Section 2. The Work Under	Consideration for Pul	blication	
Did you or your institution at any time reetc.) for any aspect of the submitted work preparation, statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the state	k (including but not limited to		
Section 3. Relevant financia	al activities outside th	e submitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount			, , ,
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you Are there any relevant conflicts of interest' Yes No			
Section 4. Intellectual Prope	erty Patents & Copy	/rights	
Do you have any patents, whether pl	anned, pending or issued	d, broadly relevant to the	w 🗌 Yes 🕡 No

Li 2



0 41	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the a box below.	bove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Li has noth	ing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Li 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical

company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, cademic institution, etc.

Quantitions from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1



Section 1. Identifying Infor	mation		
1. Given Name (First Name) Xu-Lei	Surname (Last Name Huo	e)	3. Date 27-February-2020
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's N Jun-Ting Zhang	lame
Manuscript TitlePrognostic and predictive value of an	n immune infiltration sigr	nature in diffuse lower-gra	de gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	ı know it)	_	
Section 2.			
Did you or your institution at any time re etc.) for any aspect of the submitted work preparation, statistical analysis, etc.)? Are there any relevant conflicts of int	k (including but not limited t	from a third party (governme	
Section 3. Relevant financia	al activities outside t	he submitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you Are there any relevant conflicts of interest' Yes No			
Section 4. Intellectual Prope	erty Patents & Cop	yrights	
Do you have any patents, whether p	lanned, pending or issue	ed, broadly relevant to the	w Yes 🗸 No



On officer F	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance or encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the a box below.	bove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Huo has no	othing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical

company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, cademic institution, etc.

Quantitions from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1



Section 1. Identifying Infor	mation		
Given Name (First Name) Huan	2. Surname (Last Name) Li		Date -February-2020
4. Are you the corresponding author?	Yes V No	Corresponding Author's Name	
Manuscript Title Prognostic and predictive value of ar	n immune infiltration signa	ture in diffuse lower-grade g	liomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	ı know it)		
Section 2. The Work Under	Consideration for Pub	olication	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest' Yes No			
Section 3. Relevant financia	al activities outside th	e submitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you Are there any relevant conflicts of interest' Yes No			
Section 4. Intellectual Prope	erty Patents & Copy	rights	
Do you have any patents, whether pl	lanned, pending or issued	, broadly relevant to the w	Yes 🗸 No



0 45 -	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abbox below.	pove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Li has nothi	ng to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical

company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, cademic institution, etc.

Quantitions from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1



Section 1. Identifying Infor	mation		
1. Given Name (First Name) Shu-Yu	Surname (Last Name Hao	•	3. Date 27-February-2020
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Nar Jun-Ting Zhang	me
Manuscript TitlePrognostic and predictive value of a	n immune infiltration sign	ature in diffuse lower-grade	e gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	ı know it)		
Section 2.			
Did you or your institution at any time re	Consideration for Purceive payment or services		commercial private foundation
etc.) for any aspect of the submitted wor preparation, statistical analysis, etc.)? Are there any relevant conflicts of int	k (including but not limited t		
Section 3. Relevant financia	al activities outside tl	he submitted work	
Place a check in the appropriate box			al relationships (regardless of
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you Are there any relevant conflicts of interest' Yes No			
Section 4. Intellectual Prop	erty Patents & Cop	yrights	
Do you have any patents, whether p	lanned, pending or issue	d, broadly relevant to the w	Yes No



Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance or encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
statements. On	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the a box below.	bove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Hao has no	othing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical

company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, cademic institution, etc.

Quantitions from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1



Section 1. Identifying Infor	mation		
1. Given Name (First Name) Zhen	Surname (Last Name Wu	me) 3. Date 27-February-2020	
4. Are you the corresponding author?	Yes V No	Corresponding Author's Name Jun-Ting Zhang	
Manuscript TitlePrognostic and predictive value of an	n immune infiltration sign	ature in diffuse lower-gra	de gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	ı know it)	_	
Section 2.	Consideration for Pu	18 6	
Did you or your institution at any time re etc.) for any aspect of the submitted work preparation, statistical analysis, etc.)? Are there any relevant conflicts of int	ceive payment or services t k (including but not limited t	from a third party (governme	
Section 3. Relevant financia	al activities outside th	ne submitted work.	
Place a check in the appropriate box amount of compensation) with entities as des Are there any relevant conflicts of int	scribed in the instructions	•	
Section 4. Intellectual Prope	erty Patents & Cop	yrights	
Do you have any patents, whether p	lanned, pending or issue	d, broadly relevant to the	w Yes 🗸 No



On officer F	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance or encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Otatomont
	Disclosure Statement
Based on the all box below.	bove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Wu has not	hing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical

company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, cademic institution, etc.

Quantitions from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1



Section 1. Identifying Inform	mation		
Given Name (First Name) Liang	Surname (Last Name) Wang		3. Date 27-February-2020
4. Are you the corresponding author?	Yes V No	Corresponding Author's Nar Jun-Ting Zhang	me
5. Manuscript Title Prognostic and predictive value of ar	n immune infiltration signa	ature in diffuse lower-grade	gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	know it)		
Section 2. The Work Under	Consideration for Pul	olication	
Did you or your institution at any time re etc.) for any aspect of the submitted work preparation, statistical analysis, etc.)? Are there any relevant conflicts of int	k (including but not limited to		
Section 3. Relevant financia	al activities outside th	e submitted work.	
Place a check in the appropriate box amount of compensation) with entities as des	es in the table to indicate	whether you have financia	
Section 4. Intellectual Prope	erty Patents & Copy	rights	
Do you have any patents, whether pl	anned, pending or issued	l, broadly relevant to the w	Yes V No



0 45 -	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abbox below.	pove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Wang has n	othing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical

company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, cademic institution, etc.

Quantitions from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1



Section 1. Identifying Infor	mation		
Given Name (First Name) Da	2. Surname (Last Name) Li		3. Date 27-February-2020
4. Are you the corresponding author?	Yes V No	Corresponding Author's Na Jun-Ting Zhang	ame
Manuscript Title Prognostic and predictive value of ar	n immune infiltration signa	ature in diffuse lower-grad	le gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	ı know it)		
		-	
Section 2. The Work Under	Consideration for Pul	olication	
Did you or your institution at any time re etc.) for any aspect of the submitted work preparation, statistical analysis, etc.)? Are there any relevant conflicts of int	k (including but not limited to		
Section 3. Relevant financia	al activities outside th	e submitted work.	
Place a check in the appropriate box amount of compensation) with entities as des	scribed in the instructions.	•	
Section 4. Intellectual Prope	erty Patents & Copy	rights	
Do you have any patents, whether pl	lanned, pending or issued	I, broadly relevant to the v	w ☐ Yes ✔ No



0 45 -	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abbox below.	pove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Li has nothi	ng to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1.

2.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3.

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Control Example 1 [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance,

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Zhang 1



Section 1.		
Identifying Infor	mation	
Given Name (First Name) Jun-Ting	Surname (Last Name) Zhang	3. Date 27-February-2020
4. Are you the corresponding author?	✓ Yes No	
Manuscript Title Prognostic and predictive value of ar	າ immune infiltration signature in diff	use lower-grade gliomas
6. Manuscript Identifying Number (if you 133811-INS-CMED-RV-2	know it)	
Ocation O		
Section 2. The Work Under	Consideration for Publication	
	k (including but not limited to grants, data	party (government, commercial, private foundation, a monitoring board, study design, manuscript
Section 3. Relevant financia	al activities outside the submit	ted work.
amount	scribed in the instructions. Use one I	ou have financial relationships (regardless of ine for each entity; add as many lines as you
Section 4. Intellectual Property		
Intellectual Prope	erty Patents & Copyrights	
Do you have any patents, whether pl	anned, pending or issued, broadly re	elevant to the w Yes V No

Zhang 2



On officer F	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance or encing, what you wrote in the submitted work?
	owing relationships/conditions/circumstances are present (explain below): ationships/conditions/circumstances that present a potential conflict of
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure occasion, journals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the a box below.	bove disclosures, this form will automatically generate a disclosure statement, which will appear in the
Dr. Zhang has	nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Zhang 3

Section & Topic	No	Item	Reported on page #
TITLE OR ABSTRACT	-		
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy	AUC and c-index
		(such as sensitivity, specificity, predictive values, or AUC)	were used.
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions	Yes
		(for specific guidance, see STARD for Abstracts)	
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	Included
	4	Study objectives and hypotheses	Included
METHODS			
Study design	5	Whether data collection was planned before the index test and reference standard	Retrospective study
		were performed (prospective study) or after (retrospective study)	
Participants	6	Eligibility criteria	Included
	7	On what basis potentially eligible participants were identified	LGGs with
		(such as symptoms, results from previous tests, inclusion in registry)	molecular and
			clinical information
	8	Where and when potentially eligible participants were identified (setting, location and dates)	NA
	9	Whether participants formed a consecutive, random or convenience series	Convenience series
Test methods	10a	Index test, in sufficient detail to allow replication	Yes
	10b	Reference standard, in sufficient detail to allow replication	Yes
	11	Rationale for choosing the reference standard (if alternatives exist)	NA
	12a	Definition of and rationale for test positivity cut-offs or result categories	Yes
		of the index test, distinguishing pre-specified from exploratory	
	12b	Definition of and rationale for test positivity cut-offs or result categories	NA
		of the reference standard, distinguishing pre-specified from exploratory	
	13 a	Whether clinical information and reference standard results were available	Yes
		to the performers/readers of the index test	
	13b	Whether clinical information and index test results were available	Yes
		to the assessors of the reference standard	
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	Time-dependent
			ROC curves,
	45	How indeterminate independent or reference standard receils were bondled	Harrell's C statistic
	15	How indeterminate index test or reference standard results were handled How missing data on the index test and reference standard were handled	NA Dalation
	16		Deletion
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from	NA
	40	exploratory	NIA .
	18	Intended sample size and how it was determined	NA
RESULTS			
Participants	19	Flow of participants, using a diagram	Figure 1
	20	Baseline demographic and clinical characteristics of participants	Table S1
	21a	Distribution of severity of disease in those with the target condition	Figure 4
	21b	Distribution of alternative diagnoses in those without the target condition	NA
	22	Time interval and any clinical interventions between index test and reference standard	Figure 2
Test results	23	Cross tabulation of the index test results (or their distribution)	Table S1
		by the results of the reference standard	
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Figure 4, Figure S5,
	3-	Any advorce quarte from performing the index test on the reference standard	Figure 8
DICCUCCION	25	Any adverse events from performing the index test or the reference standard	NA
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	Included
	27	Implications for practice, including the intended use and clinical role of the index test	Included



OTHER			
INFORMATION			
	28	Registration number and name of registry	NA
	29	Where the full study protocol can be accessed	Yes
	30	Sources of funding and other support; role of funders	Included



AIM

STARD stands for "Standards for Reporting Diagnostic accuracy studies". This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

EXPLANATION

A diagnostic accuracy study evaluates the ability of one or more medical tests to correctly classify study participants as having a target condition. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test.** A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or "2x2" table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on http://www.equator-network.org/reporting-guidelines/stard.

